Helicobacter pylori infection is one of the most common bacterial infections in humans. Noninvasive testing for H pylori is available using the urea breath test or a stool antigen test. Antibiotic regimens consist of a proton pump inhibitor (PPI) plus clarithromycin and amoxicillin or metronidazole/tinidazole, or a PPI plus metronidazole with bismuth and tetracycline. In clinical practice, antibiotic therapy can achieve cure rates of as high as 85%, but this rarely occurs. Thus, new therapies are needed. Because of the relatively low cure rates, follow-up confirmation of cure is needed using a urea breath test or a stool antigen test if the urea breath test is not available.
Current therapeutic approaches for Helicobacter pylori infection / Dore, Maria Pina; Graham, D. Y.. - In: DRUG BENEFITS TRENDS. - ISSN 1080-5826. - 16:4(2004), pp. 188-196.
Current therapeutic approaches for Helicobacter pylori infection
DORE, Maria Pina;
2004-01-01
Abstract
Helicobacter pylori infection is one of the most common bacterial infections in humans. Noninvasive testing for H pylori is available using the urea breath test or a stool antigen test. Antibiotic regimens consist of a proton pump inhibitor (PPI) plus clarithromycin and amoxicillin or metronidazole/tinidazole, or a PPI plus metronidazole with bismuth and tetracycline. In clinical practice, antibiotic therapy can achieve cure rates of as high as 85%, but this rarely occurs. Thus, new therapies are needed. Because of the relatively low cure rates, follow-up confirmation of cure is needed using a urea breath test or a stool antigen test if the urea breath test is not available.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.